pfs230d1m-epa/as01
Vaccineexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 6, 2016 (NCT02942277)
Timeline
Indications
Studied for
Mechanism of action
- Plasmodium falciparumImmunity, active
Plasmodium falciparum immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pfs230d1m-epa/as01
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07147400 | Phase 2 | Aug 22, 2025 | National Institute of Allergy and Infectious Diseases (NIAID), Serum Institute of India Pvt. Ltd. |
| NCT06507605 | Phase 1 | Jul 30, 2024 | National Institute of Allergy and Infectious Diseases (NIAID), Serum Institute of India Pvt. Ltd. |
| NCT03917654 | Phase 2 | Jul 5, 2019 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02942277 | Phase 1 | Oct 6, 2016 | National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 4 | 2 | 2 | 2016 |
| Serum Institute of India Pvt. Ltd. | For profit | 2 | 2 | 2 | 2024 |
2 organizations
Page 1 / 1